Armata Pharmaceuticals (ARMP) investor relations material

Strategic highlights and market positioning

• Focus on phage-based anti-infectives as alternatives to antibiotics, addressing antimicrobial resistance (AMR) and protecting the human microbiome.

• Diversified clinical pipeline targeting critical infections, including Staphylococcus aureus and Pseudomonas aeruginosa.

• Completed three randomized controlled Phase 2 trials across two programs, with positive topline results in both CF and NCFB respiratory indications and S. aureus bacteremia.

• Proprietary, US-based cGMP manufacturing platform enables high-purity, high-potency phage products and supports scalability.

• Strong leadership and partnerships, including non-dilutive funding from the US Department of Defense and Cystic Fibrosis Foundation.

Clinical pipeline and trial outcomes

• AP-SA02 for complicated S. aureus bacteremia advanced to Phase 3 after positive Phase 2a results, showing statistically significant improvement over standard of care and good safety profile.

• AP-PA02 completed Phase 2 trials in CF and NCFB, demonstrating safety, tolerability, and significant reduction in P. aeruginosa bacterial load in treated groups.

• FDA agreed Phase 2 efficacy data for AP-SA02 are sufficient to start Phase 3 trials.

• Clinical strategy includes parallel regulatory and commercial pathways, with potential for rapid approval and market expansion.

• Additional pipeline programs target prosthetic joint infections and acute respiratory infections.

Manufacturing and platform capabilities

• 10,000 sq ft in-house cGMP facility in Los Angeles supports commercial-scale production and late-stage trials.

• Proprietary processes achieve industry-leading phage purity, enabling higher dosing, repetitive IV administration, and lower cost of goods.

• Facility includes multiple production lines, high-throughput aseptic filling, and in-house quality control labs.

• Manufacturing innovations increase fermentation efficiency and product stability, reducing supply chain risks.

• Platform allows for rapid adaptation and expansion into new indications and pathogens.